Zacks: Moderna Inc (NASDAQ) (NYSE:MRNA) Given $28.88 Consensus Target Price by Analysts

Shares of Moderna Inc (NASDAQ) (NYSE:MRNA) have earned an average broker rating score of 1.19 (Strong Buy) from the eight analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a buy recommendation and six have given a strong buy recommendation to the company. Moderna Inc (NASDAQ)’s rating score has improved by 1.7% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokers have set a 1-year consensus target price of $28.88 for the company and are expecting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also given Moderna Inc (NASDAQ) an industry rank of 72 out of 256 based on the ratings given to its competitors.

Separately, Chardan Capital reissued a “buy” rating on shares of Moderna Inc (NASDAQ) in a research report on Sunday, April 7th.

NYSE MRNA traded up $0.33 on Monday, reaching $15.73. The company had a trading volume of 29,954 shares, compared to its average volume of 1,094,717. The business has a fifty day moving average price of $22.29. Moderna Inc has a 52-week low of $13.03 and a 52-week high of $29.79.

Moderna Inc (NASDAQ) (NYSE:MRNA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The company had revenue of $16.03 million during the quarter, compared to analyst estimates of $33.59 million.

About Moderna Inc (NASDAQ)

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Recommended Story: What is a dead cat bounce?

Get a free copy of the Zacks research report on Moderna Inc (NASDAQ) (MRNA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Moderna Inc (NASDAQ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc (NASDAQ) and related companies with's FREE daily email newsletter.